Lilly Company Profile

What is the competitive landscape for LILLY

LILLY has one hundred and five approved drugs.

Summary for Lilly

US Patents:	0
Tradenames:	85
Ingredients:	81
NDAs:	105

Drugs and US Patents for Lilly

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	DECABID	indecainide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019693-003	Dec 29, 1989		DISCN	No	No
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Lilly	DIETHYLSTILBESTROL	diethylstilbestrol	TABLET, DELAYED RELEASE;ORAL	004039-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	DYMELOR	acetohexamide	TABLET;ORAL	013378-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	HISTAMINE PHOSPHATE	histamine phosphate	INJECTABLE;INJECTION	000734-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Lilly

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,972,383
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003	6,821,975*PED
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-002	Jun 25, 2008	7,517,334
Lilly	CINOBAC	cinoxacin	CAPSULE;ORAL	018067-002	Approved Prior to Jan 1, 1982	3,669,965
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	6,906,086

Paragraph IV (Patent) Challenges for LILLY drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	3 mg/25 mg		2008-05-08
	For Injection	1g/vial		2005-11-14
	For Injection	100 mg/vial		2008-07-01
	For Injection	1000 mg/vial		2012-06-27
	Injection	250 mcg/mL, 2.4 mL prefilled Pen		2015-07-27
	Tablets	5 mg, 10 mg and 20 mg		2007-11-21
	Delayed-release Capsules	40 mg		2012-05-10
	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg		2005-01-10
	For Injection	200 mg/vial		2005-11-01
	For Injection	2 g/vial		2007-08-24
	For Injection	500 mg/vial		2008-02-04
	For Injection	750 mg/vial		2016-10-06
	Tablets	2.5 mg		2008-10-14
	Delayed-release Capsules	20 mg, 30 mg and 60 mg		2008-08-04
	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg		2007-05-29

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Lilly
• Lilly Res Labs

Lilly’s Market Position, Strengths, and Strategic Insights in the Pharmaceutical Industry

Last updated: March 18, 2026

What is Eli Lilly's current market position?

Eli Lilly and Company ranks among top global pharmaceutical companies, with a revenue of $28.3 billion in 2022. Its revenue distribution includes oncology (27%), neuroscience (18%), endocrinology (15%), and immunology (12%). The company maintains a significant presence in the U.S., accounting for roughly 50% of its revenue, followed by Europe and other international markets. Lilly's portfolio emphasizes innovative biologics and targeted therapies, providing a competitive edge.

How does Lilly compare to leading competitors?

Company	2022 Revenue (USD billion)	Key Focus Areas	Notable Products
Lilly	28.3	Oncology, Neuroscience, Diabetes	Trulicity, Taltz, Verzenio
Pfizer	100.3	Vaccines, Oncology, Rare Diseases	Prevnar, Ibrance, Xeljanz
Merck & Co.	59.3	Oncology, Vaccines, Infectious Disease	Keytruda, Gardasil, Merck Launchpad
Novartis	51.6	Oncology, Ophthalmology, Generics	Cosentyx, Aimovig, Lucentis
Roche	63.3	Oncology, Diagnostics, Immunology	Herceptin, Kadcyla, Tecentriq

Lilly’s focused portfolio and mid-range revenue position place it as a leader in specialized therapies, especially in diabetes and oncology. Its agility allows rapid adaptation against larger players’ broad pipelines.

What are Lilly’s key strengths?

Robust R&D pipeline

Lilly invests approximately 22% of revenue into R&D, totaling over $6 billion in 2022. Its pipeline includes promising candidates like donanemab for Alzheimer’s disease, indicating focus on neurological and precision medicine segments.

Diversified product portfolio

The company maintains a balance between established blockbusters and early-stage innovation. Key marketed products include Trulicity for diabetes, Taltz for psoriasis, and Verzenio for breast cancer. It also invests in immunology and neurodegenerative disorders.

Strategic partnerships and acquisitions

Lilly’s collaborations target innovative modalities like antibody-drug conjugates and gene therapies. Notable recent deals include the acquisition of Prevail Therapeutics in 2021 for $880 million and partnerships with AbCellera and other biotech firms.

Global expansion efforts

Strengthening its footprint outside the U.S., Lilly has expanded into emerging markets such as China and India. It has localized manufacturing and regulatory strategies to accelerate access and revenue generation.

What strategic initiatives does Lilly pursue?

Focus on neuroscience and oncology

Lilly prioritizes these areas with a pipeline targeting Alzheimer’s, Parkinson’s, multiple solid tumors, and hematologic malignancies. It aims to lead in personalized medicine, leveraging biomarkers and companion diagnostics.

Investment in cell and gene therapies

Lilly entered the cell therapy space through acquisitions and internal R&D. Its focus includes oncology, rare diseases, and neurodegeneration, aligning with broader industry trends.

Digital transformation

The company integrates digital solutions for trial management and patient engagement. It leverages real-world data and AI tools to optimize R&D and commercial strategies.

Commitment to sustainability and access

Lilly pledges to improve global health equity through affordable access programs in low-income countries and sustainable manufacturing practices.

How is Lilly positioned against current industry challenges?

• Pricing pressures: Despite innovative products, Lilly faces pricing and reimbursement challenges amid healthcare system cost containment.

• Patent expirations: Some key products face patent cliffs over the next 3-5 years, prompting accelerated pipeline development.

• Regulatory uncertainties: Evolving regulatory landscapes, especially in emerging markets, require proactive compliance strategies.

• Pipeline risks: The success of pipeline candidates like donanemab remains uncertain, with high clinical and regulatory risk.

Key Takeaways

• Lilly ranks high among mid-cap global pharmaceutical firms, with a strategic focus on oncology and neurodegenerative disease.
• R&D investment drives a competitive pipeline, emphasizing personalized therapies.
• Partnerships and acquisitions augment technological capabilities and expand product offerings.
• Global expansion and digital initiatives position Lilly for growth amid industry challenges.
• Sustained innovation and strategic agility will determine its future market share and profitability.

FAQs

1. How does Lilly's patent expiry outlook affect its future revenue?
Lilly faces patent expirations for some high-revenue drugs, such as Trulicity (expected loss of exclusivity in 2028). This creates revenue risks but also prompts accelerated pipeline development and potential pipeline diversification.

2. What are Lilly’s most promising pipeline candidates?
Donanemab (Alzheimer’s), presymptomatic psychiatric therapies, and oncology therapies targeting CDK4/6 and PI3K pathways are among its most promising candidates.

3. How does Lilly leverage digital health innovations?
Lilly incorporates real-world evidence, AI-driven drug discovery, and digital patient engagement platforms to streamline clinical development and improve treatment adherence.

4. How significant are Lilly’s international growth initiatives?
International markets, especially China and India, contribute roughly 25% of revenue, with localized products and partnerships facilitating growth.

5. What strategic risks should investors monitor?
Pipeline failure, patent cliffs, regulatory hurdles, and pricing pressures remain key risks impacting Lilly’s future performance.

---

References

[1] Eli Lilly and Company. (2023). Annual Report 2022.
[2] IQVIA. (2022). The Global Use of Medicines in 2022.
[3] Statista. (2023). Top pharmaceutical companies by revenue.
[4] EvaluatePharma. (2023). World Market Outlook.
[5] Reuters. (2022). Eli Lilly’s pipeline and strategic initiatives review.